NCT05662293 Characterization of Arrhythmia-induced Cardiomyopathy
| NCT ID | NCT05662293 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Cardiomyopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,700 participants |
| Start Date | 2021-06-10 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,700 participants in total. It began in 2021-06-10 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the this observational study is to gather clinically available data on patients presenting with a suspicion for arrhythmia-induced cardiomyopathy (AiCM) at the University Hospital Basel.
Eligibility Criteria
Prospective part Inclusion Criteria: * Diagnostic or suspicion of AiCM as presence of specified keyword in patient's file or as screened by colleagues of the internal medicine or cardiology clinics * Signed study consent Exclusion Criteria: * Patient's active refusal of the general consent of the University Hospital Basel * Age \<18 years old * Temporary exclusion criteria: Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (\>100 bpm, \<90 systolic BP, evidence of organ dysfunction). * Life expectancy \<1 year (palliative, terminal cancer) Retrospective part Inclusion Criteria: * Patients with a reduced left-ventricular ejection fraction (LVEF ≤50%) or a reduction of 15% in the ejection fraction (EF) between two echocardiographies and a concomitant diagnosis of any arrhythmia likely to lead to AiCM within one year before or after diagnosis of the reduced LVEF from 2010-2021 Exclusion Criteria: * Age \< 18 years old * Patient's active refusal of the general consent of the University Hospital Basel * Acute event clearly leading to an acutely reduced LVEF (massive type I myocardial infarction, cardiogenic shock from a coronary or myocardial etiology, septic shock leading to toxic myopathy, hypovolemic shock with reduced EF, cardiac arrest and/or need for resuscitation). * Patients with life expectancy \<1 year (palliative, terminal cancer)
Contact & Investigator
Patrick Badertscher, MD
PRINCIPAL INVESTIGATOR
University Hospital Basel, Department of Cardiology
Frequently Asked Questions
Who can join the NCT05662293 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiomyopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05662293 currently recruiting?
Yes, NCT05662293 is actively recruiting participants. Contact the research team at patrick.badertscher@usb.ch for enrollment information.
Where is the NCT05662293 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT05662293 clinical trial?
NCT05662293 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Patrick Badertscher, MD at University Hospital Basel, Department of Cardiology. The trial plans to enroll 2,700 participants.